PMID- 21184268
OWN - NLM
STAT- MEDLINE
DCOM- 20110505
LR  - 20151119
IS  - 1573-7217 (Electronic)
IS  - 0167-6806 (Linking)
VI  - 126
IP  - 1
DP  - 2011 Feb
TI  - Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in 
      hormone receptor-positive breast cancer.
PG  - 93-9
LID - 10.1007/s10549-010-1315-z [doi]
AB  - Cross-talk between the estrogen receptor and the mammalian target of rapamycin 
      (mTOR) pathway is one of the mechanisms of endocrine therapy resistance, and the 
      phosphorylated S6 kinase 1(p-S6K1) is known to be a marker of the mTOR pathway 
      activation. The authors assessed the prognostic significance of p-S6K1 according 
      to the hormone receptor (HR) status. The expression of p-S6K1 was evaluated in 
      304 breast cancer tissues, and the association between its expression and patient 
      outcomes was investigated. Among 197 cases with the HR (+) tumor, 70 (35.5%) were 
      positive for p-S6K1. Most of the patients (97.5%) with the HR (+) tumor received 
      adjuvant endocrine therapy. The expression of p-S6K1 was found to be an 
      independent worse prognosticator affecting overall survival (OS) and breast 
      cancer-specific survival (BCSS) in the HR (+) group (hazard ratio, 2.62; 95% 
      confidence interval [CI], 1.19-5.76; P = 0.017 and hazard ratio, 3.25; 95% CI, 
      1.20-8.82; P = 0.020, respectively). In the HR (-) group, however, the p-S6K1 
      expression was not associated with patients' survival. The expression of p-S6K1 
      is a worse prognostic factor in patients with HR (+) tumors. These results 
      suggest that the p-S6K1 expression might be a marker for endocrine therapy 
      resistance in patients with HR (+) tumors.
FAU - Kim, Eun-Kyu
AU  - Kim EK
AD  - Department of Surgery, Korea Cancer Center Hospital, Korea Institute of 
      Radiological and Medical Sciences, Nowon-gu, Seoul, 139-706, Korea.
FAU - Kim, Hyun-Ah
AU  - Kim HA
FAU - Koh, Jae Soo
AU  - Koh JS
FAU - Kim, Min Suk
AU  - Kim MS
FAU - Kim, Kwan-Il
AU  - Kim KI
FAU - Lee, Jong Inn
AU  - Lee JI
FAU - Moon, Nan Mo
AU  - Moon NM
FAU - Ko, Eunyoung
AU  - Ko E
FAU - Noh, Woo Chul
AU  - Noh WC
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20101224
PL  - Netherlands
TA  - Breast Cancer Res Treat
JT  - Breast cancer research and treatment
JID - 8111104
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - EC 2.7.11.1 (Ribosomal Protein S6 Kinases, 70-kDa)
RN  - EC 2.7.11.1 (ribosomal protein S6 kinase, 70kD, polypeptide 1)
SB  - IM
MH  - Antineoplastic Agents, Hormonal/therapeutic use
MH  - Biomarkers, Tumor/metabolism
MH  - Breast Neoplasms/drug therapy/*metabolism/pathology
MH  - Carcinoma, Ductal, Breast/drug therapy/*metabolism/pathology
MH  - *Drug Resistance, Neoplasm
MH  - Female
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Middle Aged
MH  - Neoplasm Staging
MH  - Phosphorylation
MH  - Prognosis
MH  - Prospective Studies
MH  - Receptor, ErbB-2/*metabolism
MH  - Receptors, Estrogen/*metabolism
MH  - Receptors, Progesterone/*metabolism
MH  - Ribosomal Protein S6 Kinases, 70-kDa/*metabolism
MH  - Survival Rate
MH  - Tissue Array Analysis
EDAT- 2010/12/25 06:00
MHDA- 2011/05/06 06:00
CRDT- 2010/12/25 06:00
PHST- 2010/09/15 00:00 [received]
PHST- 2010/12/16 00:00 [accepted]
PHST- 2010/12/25 06:00 [entrez]
PHST- 2010/12/25 06:00 [pubmed]
PHST- 2011/05/06 06:00 [medline]
AID - 10.1007/s10549-010-1315-z [doi]
PST - ppublish
SO  - Breast Cancer Res Treat. 2011 Feb;126(1):93-9. doi: 10.1007/s10549-010-1315-z. 
      Epub 2010 Dec 24.